Drug companies ask Oklahoma judge to dismiss opioid lawsuit
OKLAHOMA CITY (AP) — Drug companies have asked a judge to dismiss a lawsuit filed by Oklahoma's attorney general accusing them of fueling the state's opioid epidemic through fraudulent marketing.
Insider Q&A: Allergan CEO on impact of limiting price hikes
As drugmakers pushed back against rising criticism over sky-high U.S. prescription drug prices, one pharmaceutical company went public with a pledge.
Brent Saunders, CEO of Botox maker Allergan PLC, last September announced a new "social contract" under which the company would limit annual list price increases for its drugs to below 10 percent.
Allergan paying $639 million for Vitae Pharmaceuticals
NEW YORK (AP) — Allergan will buy Vitae Pharmaceuticals Inc. for $639 million, adding potential dermatology products to its development pipeline.
Ireland-based Allergan is best known for Botox, a blockbuster wrinkle treatment. The drug is also approved to treat muscle spasms and bladder control.
Pfizer on buying spree with AstraZeneca antibiotics deal
TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. is continuing its shopping spree with its fourth acquisition since the April collapse of its planned $160 billion megadeal to buy rival Allergan PLC and move its headquarters, on paper, to Allergan's base in lower-tax Ireland.
Rising sales of Pfizer Inc.'s key new medicines and prospects that more drugs will be approved soon have analysts speculating the biggest U.S. drugmaker won't break up after all.
For five years, the maker of Viagra and fibromyalgia and pain treatment Lyrica has been mulling a split up that might enable the resulting pieces to grow faster.
The impetus seemed to come from analysts, not Pfizer management. Over that stretch, Pfizer bought several companies and products,...
- Globe NewswireDermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of DirectorsMay 15, 2019
- Business WirePatientFi® Announces Study Partnership with AllerganMay 15, 2019
- Globe NewswireAllergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10)April 29, 2019